ThermoWave MHT is the first non-ionizing radiotherapy that can raise internal target temperature to 44°C to depths of 1-15 cm causing vasodilation and hypervascularization with an influx of 1500% more blood flow and oxygen without damage to healthy tissue.
The proprietary dual modality technology of ThermoWave penetrates biological tissue generating heat 1-15 cm deep using a flexible, multi-layer meta-material treatment pad with micro-sensors. This provides continuous temperature monitoring for maximum safety, efficacy and comfort.
ThermoWave Therapy can be used alone or in combination with chemotherapy, radiation therapy or surgery. ThermoWave:
ThermoWave has a sophisticated auto-calibration system that precisely matches the physical characteristics of the biological tissue, while maintaining surface temperature and preventing injury without any need for cooling. Micro-sensors in the treatment pad continuously monitor and control both internal and external temperatures for safe, effective and consistent delivery of heat energy directly to the treatment area.
The initial pilot study validating the technology was conducted at the University of Tennessee on late stage cancer patients including: 2 horses, 2 dogs and 2 cats.
ThermoWave Therapy results in rapid apoptosis, reduced pain and accelerated healing, as never before possible. And, it is an affordable tabletop unit, so the veterinary market is finally able to access the most powerful, safe and effective molecular hyperthermia technology that exists for cancer treatment.
For oncology research centers, ThermoWave MHT makes a valuable low-cost addition to oncology research because the institutional XL model directly integrates with MRI and other radiotherapy technologies for real-time continuous monitoring of energy delivery and biological changes.
ThermoWave MHT Responses
Download additional information:
To find out more about ThermoWave, please complete this form and we’ll get back to you.